Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Apixaban is currently indicated in Europe for the prevention of VTE in patients who have undergone total knee replacement or total hip replacement. Apixaban is also being investigated in Phase III ...